Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Antengene Corporation Limited ( (HK:6996) ) just unveiled an update.
Antengene Corporation Limited announced that its drug XPOVIO (selinexor), in combination with bortezomib and dexamethasone, has been approved for reimbursement in Taiwan’s National Health Insurance scheme starting March 1, 2025. This approval marks a significant milestone for Antengene, potentially boosting its market presence in Taiwan and enhancing its competitive positioning in the biopharmaceutical industry, particularly in the treatment of relapsed/refractory multiple myeloma.
More about Antengene Corporation Limited
Antengene Corporation Limited is a leading commercial-stage R&D-driven global biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of innovative therapeutics for hematologic malignancies and solid tumors. Since 2017, the company has developed a pipeline of nine oncology assets, including six with global rights, and has received numerous investigational new drug approvals in the U.S. and Asia.
YTD Price Performance: 62.50%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €78.28M
For detailed information about 6996 stock, go to TipRanks’ Stock Analysis page.